Saturday, June 19, 2004

More on Registries for Clinical Trials of Pharmaceuticals

According to today's NYT, GlaxoSmithKline has agreed to list all clinical trials of its marketed drugs on a web site. Meanwhile, Merck has announced support for the AMA's proposal to establish a government registry for clinical trials. Are there any substantial arguments against such transparency? We can't think of any -- not, at least, for drugs that make it to market.


Post a Comment

<< Home

Fed. R. Evid. 702: If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.